Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 16, 2013, Pages

  Shchors, Ksenya ^a,b,c   Persson, Anders I ^a,d   Rostker, Fanya ^a   Tihan, Tarik ^a   Lyubynska, Natalya ^a   Li, Nan ^a,d   Swigart, Lamorna Brown ^a   Berger, Mitchel S ^a,d   Hanahan, Douglas ^c   Weiss, William A ^a,b,d   Evan, Gerard I ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EPFL   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; PROTEIN MDM2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME INACTIVATION; GENE FREQUENCY; GENE SWITCHING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HISTOLOGICAL TECHNIQUES; HUMANS; IMMUNOBLOTTING; KAPLAN-MEIER ESTIMATE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTATION; PROTO-ONCOGENE PROTEINS C-MDM2; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MUS;

EID: 84876245628     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1219142110     Document Type: Article

References (54)

1. Rand V, et al. (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci USA 102(40):14344-14349.
2. McLendon R; Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068.
3. Takahashi T, et al. (1989) p53: A frequent target for genetic abnormalities in lung cancer. Science 246(4929):491-494.
4. Malkin D, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233-1238.
5. Rodrigues NR, et al. (1990) p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87(19):7555-7559.
6. Osman I, et al. (1999) Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression. Clin Cancer Res 5(8):2082-2088.
7. Laurie NA, et al. (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444(7115):61-66.
8. Vonlanthen S, et al. (1998) Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene 17(21):2779-2785.
9. Maestro R, et al. (1999) Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13(17):2207-2217.
10. Silva J, et al. (2001) Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene 20(33):4586-4590.
11. Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. Acta Neuropathol 101(3):185-189.
12. Maeda T, et al. (2005) Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433(7023):278-285.
13. Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-oncol 1(1):44-51.
14. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H (1997) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56(2):180-185.
15. Fulci G, et al. (2000) p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19(33):3816-3822.
16. Watanabe K, et al. (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6(3):217-223; discussion 223-214.
17. Verhaak RG, et al.; Cancer Genome Atlas Research Network (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98-110.
18. Hegi ME, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003.
19. Weller M, et al. (2010) MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? Nat Rev Neurol 6(1):39-51.
20. Yan H, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8): 765-773.
21. Haas-Kogan DA, et al. (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97(12):880-887.
22. Weller M, Stupp R, Hegi M, Wick W (2012) Individualized targeted therapy for glioblastoma: Fact or fiction? Cancer J 18(1):40-44.
23. Swisher SG, et al. (2003) Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101.
24. Weinmann L, et al. (2008) A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 15(4):718-729.
25. Selivanova G (2010) Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 20(1):46-56.
26. Stupp R, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996.
27. Dinca EB, et al. (2008) p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 68(24):10034-10039.
28. Lang FF, et al. (2003) Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J Clin Oncol 21(13):2508-2518.
29. Ding H, et al. (2001) Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61(9):3826-3836.
30. Kamnasaran D, Qian B, Hawkins C, Stanford WL, Guha A (2007) GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model. Proc Natl Acad Sci USA 104(19):8053-8058.
31. Munoz D (2009) Transgenic mouse models of CNS tumors, using genetically engineered murine models to study the role of p21-Ras in glioblastoma multiforme. CNS Cancer Drug Discovery and Development, ed Van Meir EG (Humana Press, New York), pp 61-76.
32. Agnihotri S, et al. (2011) A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. J Exp Med 208(4):689-702.
33. Christophorou MA, et al. (2005) Temporal dissection of p53 function in vitro and in vivo. Nat Genet 37(7):718-726.
34. Donehower LA, et al. (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9(7): 882-895.
35. French JE, et al. (2001) Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent. Carcinogenesis 22(1):99-106.
36. Vogel KS, et al. (1999) Mouse tumor model for neurofibromatosis type 1. Science 286(5447):2176-2179.
37. Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127(7):1323-1334.
38. Junttila MR, et al. (2010) Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468(7323):567-571.
39. Murphy DJ, et al. (2008) Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14(6):447-457.
40. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92(6):725-734.
41. Honda R, Yasuda H (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18(1):22-27.
42. Sarkisian CJ, et al. (2007) Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9(5):493-505.
43. Huey R, Rosenzweig F (2009) Laboratory evolution meets Catch-22. Experimental Evolution Concepts, Methods, and Applications of Selection Experiments, eds Garland T, Jr, and Rose MR (University of California Press, Berkeley, CA), pp 671-701.
44. Ishii N, et al. (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9(3):469-479.
45. Lambert JM, et al. (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15(5):376-388.
46. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170(5):1445-1453.
47. Hayashi Y, et al. (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7(3):871-875.
48. Brennan C, et al. (2009) Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4(11):e7752.
49. Chow LM, et al. (2011) Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19(3):305-316.
50. Zhu Y, et al. (2005) Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8(2):119-130.
51. Mandinova A, Lee SW (2011) The p53 pathway as a target in cancer therapeutics: Obstacles and promise. Sci Transl Med 3(64):rv1.
52. Bowman SP, Leake A, Morris ID (1982) Hypothalamic, pituitary and uterine cytoplasmic and nuclear oestrogen receptors and their relationship to the serum concentration of tamoxifen and its metabolite, 4-hydroxytamoxifen, in the ovariectomized rat. J Endocrinol 94(2):167-175.
53. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI (2006) Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10(6): 501-514.
54. Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3(3):255-268.